The effect of immune correlates on the precision of vaccine efficacy evaluation: demographic subgroups
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985807%3A_____%2F23%3A00576946" target="_blank" >RIV/67985807:_____/23:00576946 - isvavai.cz</a>
Výsledek na webu
<a href="https://iscb.international/wp-content/uploads/2023/08/Book-of-Abstract-ISCB44_25-AGO-2.pdf" target="_blank" >https://iscb.international/wp-content/uploads/2023/08/Book-of-Abstract-ISCB44_25-AGO-2.pdf</a>
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The effect of immune correlates on the precision of vaccine efficacy evaluation: demographic subgroups
Popis výsledku v původním jazyce
ZÁKLADNÍ ÚDAJE: ISCB44: 44th Annual Conference of the International Society for Clinical Biostatistics: Final Programme & Abstract Book. Milano: ISCB, 2023. s. 310-310. [ISCB 2023: Annual Conference of the International Society for Clinical Biostatistics /44./. 27.08.2023-31.08.2023, Milano]. ABSTRAKT: Clinical trials assessing vaccine efficacy typically provide data on binary and time-to-event clinical endpoints along with subjectspecific characteristics such as immune response to vaccination (immunogenicity) and demographics. Immunogenicity measurements often represent an established or a putative correlate of protection. Simulations have previously revealed that the understanding of efficacy in demographic subgroups can be substantially improved by quantifying the relationship betweenimmunogenicity and probability of disease (or of another binary clinical endpoint) and integrating that relationship with observed immunogenicity data to obtain relatively precise estimates of efficacy in subgroups of interest.
Název v anglickém jazyce
The effect of immune correlates on the precision of vaccine efficacy evaluation: demographic subgroups
Popis výsledku anglicky
ZÁKLADNÍ ÚDAJE: ISCB44: 44th Annual Conference of the International Society for Clinical Biostatistics: Final Programme & Abstract Book. Milano: ISCB, 2023. s. 310-310. [ISCB 2023: Annual Conference of the International Society for Clinical Biostatistics /44./. 27.08.2023-31.08.2023, Milano]. ABSTRAKT: Clinical trials assessing vaccine efficacy typically provide data on binary and time-to-event clinical endpoints along with subjectspecific characteristics such as immune response to vaccination (immunogenicity) and demographics. Immunogenicity measurements often represent an established or a putative correlate of protection. Simulations have previously revealed that the understanding of efficacy in demographic subgroups can be substantially improved by quantifying the relationship betweenimmunogenicity and probability of disease (or of another binary clinical endpoint) and integrating that relationship with observed immunogenicity data to obtain relatively precise estimates of efficacy in subgroups of interest.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30303 - Infectious Diseases
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2023
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů